Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients

被引：36
|
作者：
Wang, Zhan [1 ]
Chen, Juan [2 ,3 ]
Zhong, Mei-Zuo [1 ]
Huang, Juan [4 ]
Hu, Yuan-Ping [4 ]
Feng, De-Yun [5 ]
Zhou, Zhi-Jiao [6 ]
Luo, Xiao [7 ]
Liu, Zhao-Qian [2 ,3 ]
Jiang, Wu-Zhong [1 ]
Zhou, Wei-Bing [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Hunan, Peoples R China
[4] Hunan Prov Clin Meditech Res Ctr Breast Canc, Changsha 410008, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Pathol, Changsha 410013, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Hosp 3, Dept Pain, Changsha 410013, Hunan, Peoples R China
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2017年 / 79卷 / 03期
基金：
中国国家自然科学基金;
关键词：
ANLN; Breast cancer; Anthracycline; Prognosis; BINDING PROTEIN ANILLIN; DNA ADDUCTS; CYCLIN D1; ADJUVANT THERAPY; DOXORUBICIN; REPAIR; CYCLOPHOSPHAMIDE; EXPRESSION; RECOMBINATION; ACTIVATION;
D O I：
10.1007/s00280-017-3248-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy. This study enrolled 308 breast cancer patients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed. Our results showed that ANLN expression was associated with survival of breast cancer patients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancer patients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy. ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancer patients.
引用
收藏
页码：535 / 543
页数：9
相关论文
共 50 条
  • [1] Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients
    Zhan Wang
    Juan Chen
    Mei-Zuo Zhong
    Juan Huang
    Yuan-Ping Hu
    De-Yun Feng
    Zhi-Jiao Zhou
    Xiao Luo
    Zhao-Qian Liu
    Wu-Zhong Jiang
    Wei-Bing Zhou
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 535 - 543
  • [2] Anthracycline-based adjuvant chemotherapy in breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    LANCET, 2010, 375 (9729): : 1871 - 1871
  • [3] Optimum anthracycline-based chemotherapy for early breast cancer
    Adlard, Julian W.
    Dodwell, David J.
    LANCET ONCOLOGY, 2001, 2 (08): : 469 - 474
  • [4] Docetaxel and anthracycline-based neoadjuvant chemotherapy in breast cancer
    Tiezzi, D. G.
    Andrade, J. M.
    Macchetti, A. H.
    Clagnan, W. S.
    Marana, H. R.
    Zola, F. E.
    Peria, F. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Late-onset cardiotoxicity in Anthracycline-based chemotherapy for breast cancer patients
    Mata Caballero, R.
    Serrano Antolin, J. M.
    Gonzalez Garcia, I. A.
    Muniz Garcia, J.
    Curcio Ruigomez, A.
    Gutierrez Landaluce, C.
    Morales Garcia, L. J.
    Del Castillo Arrojo, S.
    Guerra Martinez, J. A.
    Graupner Abad, C.
    Jimenez Hernandez, R. M.
    Cristobal Varela, C.
    Malon Gimenez, D.
    Talavera Calle, P.
    Alonso Martin, J. J.
    EUROPEAN HEART JOURNAL, 2016, 37 : 118 - 119
  • [6] Oxidative and antioxidative status after anthracycline-based chemotherapy in breast cancer patients
    Alacacioglu, A.
    Kebapcilar, L.
    Pamuk, B. Onder
    Sop, G.
    Kucukiravul, C.
    Bozkaya, G.
    Yuksel, A.
    Alacacioglu, I.
    Sari, I.
    JOURNAL OF BUON, 2013, 18 (03): : 614 - 618
  • [7] Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer
    Mills, Paul J.
    Ancoli-Israel, Sonia
    Parker, Barbara
    Natarajan, Loki
    Hong, Suzi
    Jain, Shamini
    Sadler, Georgia R.
    von Kaenel, Roland
    BRAIN BEHAVIOR AND IMMUNITY, 2008, 22 (01) : 98 - 104
  • [8] Predictive factors for anthracycline-based chemotherapy for human breast cancer
    Miyoshi, Yasuo
    Kurosumi, Masafumi
    Kurebayashi, Junichi
    Matsuura, Nariaki
    Takahashi, Masato
    Tokunaga, Eriko
    Egawa, Chiyomi
    Masuda, Norikazu
    Kono, Seishi
    Morimoto, Koji
    Kim, Seung Jin
    Okishiro, Masatsugu
    Yanagisawa, Tetsu
    Ueda, Satsuki
    Taguchi, Tetsuya
    Tamaki, Yasuhiro
    Noguchi, Shinzaburo
    BREAST CANCER, 2010, 17 (02) : 103 - 109
  • [9] FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer
    Xu, Y. L.
    Yao, R.
    Li, J.
    Zhou, Y. D.
    Mao, F.
    Pan, B.
    Sun, Q.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1205 - 1213
  • [10] Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy
    Viens, P
    Jacquemier, J
    Bardou, VJ
    Bertucci, F
    Penault-Llorca, F
    Puig, B
    Gravis, G
    Oziel-Taïeb, S
    Resbeut, M
    Houvenaeghel, G
    Camerlo, J
    Birbaum, D
    Hassoun, J
    Maraninchi, D
    BREAST CANCER RESEARCH AND TREATMENT, 1999, 54 (03) : 205 - 212
12345